![CERo Therapeutics Holdings Inc](/common/images/company/N_CERO.png)
Company anticipates initial human trials to focus on AML upon IND clearance SOUTH SAN FRANCISCO, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO...
Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq:...
Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- CERo...
SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation...
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next...
CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0116 | 5.93350383632 | 0.1955 | 0.2689 | 0.18 | 8896902 | 0.22432354 | CS |
4 | -0.111 | -34.8946872053 | 0.3181 | 0.367608 | 0.165 | 6751263 | 0.22544407 | CS |
12 | -1.2129 | -85.4154929577 | 1.42 | 1.71 | 0.165 | 2916749 | 0.27891308 | CS |
26 | -5.0429 | -96.0552380952 | 5.25 | 12.38 | 0.165 | 2197285 | 1.10254152 | CS |
52 | -5.0429 | -96.0552380952 | 5.25 | 12.38 | 0.165 | 2197285 | 1.10254152 | CS |
156 | -5.0429 | -96.0552380952 | 5.25 | 12.38 | 0.165 | 2197285 | 1.10254152 | CS |
260 | -5.0429 | -96.0552380952 | 5.25 | 12.38 | 0.165 | 2197285 | 1.10254152 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.